Fulcrum Therapeutics (FULC) Stock Forecast & Price Target

$8.54

-0.09 (-1.04%)

(As of 09/6/2024 ET)

Fulcrum Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Fulcrum Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for FULC.

Consensus Price Target

$16.33
91.26% Upside

High Forecast	$23.00
Average Forecast	$16.33
Low Forecast	$14.00

According to the 6 analysts' twelve-month price targets for Fulcrum Therapeutics, the average price target is $16.33. The highest price target for FULC is $23.00, while the lowest price target for FULC is $14.00. The average price target represents a forecasted upside of 91.26% from the current price of $8.54.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	Buy	Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$16.33	$15.57	$15.57	$11.25
Forecasted Upside	91.26% Upside	93.23% Upside	97.82% Upside	100.82% Upside

Get Fulcrum Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.

Ad Paradigm Press

Ex-CIA Advisor: “This is How Kamala will Rig the Election”

A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…

Click here now and learn how to prepare.

FULC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FULC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fulcrum Therapeutics Stock vs. The Competition

Type	Fulcrum Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	91.26% Upside	1,206.55% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/1/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00	+79.51%
7/10/2024	Cantor Fitzgerald 3 of 5 stars	K. Kluska Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$23.00 ➝ $23.00	+241.25%
5/14/2024	Oppenheimer 3 of 5 stars		Lower Target	Outperform ➝ Outperform	$16.00 ➝ $14.00	+90.48%
5/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$6.00 ➝ $15.00	+104.08%
3/13/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$14.00	+28.32%
2/28/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$13.00 ➝ $15.00	+40.58%
Get the Latest News and Ratings for FULC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/22/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$4.00 ➝ $11.00	+180.61%
3/10/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight	$8.00 ➝ $7.00	+52.17%
3/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$18.00 ➝ $10.00	+121.73%
3/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$11.00 ➝ $8.00	+65.97%
2/24/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:53 PM ET.

FULC Forecast - Frequently Asked Questions

What is Fulcrum Therapeutics' forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Fulcrum Therapeutics is $16.33, with a high forecast of $23.00 and a low forecast of $14.00.
Should I buy or sell Fulcrum Therapeutics stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FULC shares.
Does Fulcrum Therapeutics's stock price have much upside?: According to analysts, Fulcrum Therapeutics's stock has a predicted upside of 86.70% based on their 12-month stock forecasts.
What analysts cover Fulcrum Therapeutics?: Fulcrum Therapeutics has been rated by research analysts at Cantor Fitzgerald, and HC Wainwright in the past 90 days.
Do Wall Street analysts like Fulcrum Therapeutics more than its competitors?: Analysts like Fulcrum Therapeutics more than other "medical" companies. The consensus rating for Fulcrum Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FULC compares to other companies.